All In Biotech

Drug Trial Radar · NCT03794544

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Subjects With Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)

Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

84

Actual

Start

Mar 8, 2019

Primary completion

Jan 13, 2021

Study completion Jan 13, 2021

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 102 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I \[\>2cm\] to IIIA) non-small cell lung cancer (NSCLC).

Conditions

  • Resectable
  • Early-stage
  • NSCLC

Interventions

  • DurvalumabDrug

    Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

  • OleclumabCombination product

    Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

  • MonalizumabCombination product

    Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

  • DanvatirsenCombination product

    Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Pathological Response RateTime frame: Day 1 through Day 42

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California

  • Research Site

    Fort Myers, Florida

  • Research Site

    Leesburg, Florida

  • Research Site

    Baltimore, Maryland

  • Research Site

    Buffalo, New York

  • Research Site

    New York, New York

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Marseille, France

  • Research Site

    Toulouse, France

  • Research Site

    Orbassano, Italy

  • Research Site

    Porto, Portugal

  • Research Site

    A Coruña, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.